SML3705

Olaparib

≥98% (HPLC), PARP-1, PARP-2 inhibitor, powder

• Synonym(s): 1-(Cyclopropylcarbonyl)-4-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]piperazine, 4-[[3-[[4-(Cyclopropylcarbonyl)-1-piperazinyl]carbonyl]-4-fluorophenyl]methyl]-1(2H)-phthalazinone, AZD-2281, KU-0059436
• Empirical Formula (Hill Notation): C₂₄H₂₃FN₄O₃
• CAS Number: 763113-22-0
• Molecular Weight: 434.46
• UNSPSC Code: 12352200
• NACRES: NA.77
• MDL number: MFCD13185161
• Assay: ≥98% (HPLC)
• Form: powder

Properties

• Product Name: Olaparib, ≥98% (HPLC)
• Quality Segment: 100
• assay: ≥98% (HPLC)
• form: powder
• color: white to beige
• solubility: DMSO: 2 mg/mL, clear (Warmed)
• storage temp.: -10 to -25°C
• SMILES string: Fc1c(cc(cc1)C=C4NNC(=O)c5c4cccc5)C(=O)N2CCN(CC2)C(=O)C3CC3
• InChI: 1S/C24H23FN4O3/c25-20-8-5-15(14-21-17-3-1-2-4-18(17)22(30)27-26-21)13-19(20)24(32)29-11-9-28(10-12-29)23(31)16-6-7-16/h1-5,8,13-14,16,26H,6-7,9-12H2,(H,27,30)
• InChI key: JQYIJKFTPJWNFM-UHFFFAOYSA-N

Description

Biochem/physiol Actions

Antineoplastic; Poly(ADP-ribose) polymerases-1 and 2 (PARP-1, PARP-2) inhibitor

Olaparib is an antineoplastic and potent inhibitor of poly(ADP-ribose) polymerases-1 and 2 (PARP-1, PARP-2) with an IC50 of 5 nM for PARP-1 and an IC50 of 1 nM for PARP-2. Olaparib is indicated to treat breast cancer, ovarian cancer, fallopian tube cancer, peritoneal cancer, pancreatic cancer, and prostate cancer.

Safety Information

• pictograms: GHS06,GHS08
• signalword: Danger
• hcodes: H301,H360D
• pcodes: P202 - P264 - P280 - P301 + P310 - P405 - P501
• Hazard Classifications: Acute Tox. 3 Oral - Repr. 1B
• Storage Class: 6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
• wgk: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable